Étiquette : épidémiologie

Cannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data, Kent E. Hutchison et al., 2019

Cannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data Kent E. HUTCHISON, Sarah L. HAGERTY, Jeffrey GALINKIN, Angela D. BRYAN, L. Cinnamon BIDWELL Cannabis and Cannabinoid Research, 2019, 4, (3), 158-164. Doi : 10.1089/can.2018.0052   Abstract The high prevalence of chronic pain conditions combined with an over-reliance on opioid prescriptions has resulted in an opioid epidemic and a desperate need for solutions. There is some debate about whether cannabis might play a role in addressing chronic pain conditions as well as the opioid epidemic. Recent surveys suggest that a large number of people are using cannabis as a treatment for [...]

Lire la suite

Cannabis-related diagnosis in pregnancy and adverse maternal and infant outcomes, Gretchen Bandoli et al., 2021

Cannabis-related diagnosis in pregnancy and adverse maternal and infant outcomes Gretchen Bandoli, Laura Jelliffe-Pawlowski, Benjamin Schumacher, Rebecca J. Baer, Jennifer N. Felder, Jonathan D. Fuchs, Scott P. Oltman, Martina A. Steurer, Carla Marienfeld Drug and Alcohol Dependence, 2021, 225, 108757. doi : 10.1016/j.drugalcdep.2021.108757   Abstract Background: Cannabis use and cannabis use disorders are increasing in prevalence, including among pregnant women. The objective was to evaluate the association of a cannabis-related diagnosis (CRD) in pregnancy and adverse maternal and infant outcomes. Methods: We queried an administrative birth cohort of singleton deliveries in California between 2011-2017 linked to maternal and infant hospital discharge records. We [...]

Lire la suite

Cannabis : An Emerging Treatment for Common Symptoms in Older Adults, Kevin H. Yang et al., Medscape.com, 2021

Cannabis : An Emerging Treatment for Common Symptoms in Older Adults Kevin H. Yang, BS; Christopher N. Kaufmann, PhD, MHS; Reva Nafsu, LVN; Ella T. Lifset; Khai Nguyen, MD, MHS; Michelle Sexton, ND; Benjamin H. Han, MD, MPH; Arum Kim, MD; Alison A. Moore, MD, MPH Journal of American Geriatric Society, 2021, 69, (1), 91-97. https://www.medscape.com/viewarticle/945238   Abstract and Introduction Abstract Background/Objectives: Use of cannabis is increasing in a variety of populations in the United States; however, few investigations about how and for what reasons cannabis is used in older populations exist. Design: Anonymous survey. Setting: Geriatrics clinic. Participants: A total of 568 adults 65 years and older. Intervention: Not applicable. Measurements: [...]

Lire la suite

Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia, Nathan A. Gillespie, Kenneth S. Kendler, 2020

Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia Nathan A. Gillespie, Kenneth S. Kendler JAMA Psychiatry,  Published online November 4, 2020   Cohort studies and meta-analyses have documented a robust association between cannabis use, heavy use, and misuse with future risk of schizophrenia.1-3 Despite adjusting for covariates, including current psychotic symptoms, other psychopathology, and social integration,(1) the ability of these models to determine the degree to which cannabis causes schizophrenia is limited and dependent on their ability to capture all relevant confounders. When evaluating efforts to reduce cannabis use as a means of [...]

Lire la suite

Trajectories of Nicotine and Cannabis Vaping and Polyuse. From Adolescence to Young Adulthood, H. Isabella Lanza, 2020

Trajectories of Nicotine and Cannabis Vaping and Polyuse. From Adolescence to Young Adulthood H. Isabella Lanza, PhD; Jessica L. Barrington-Trimis, PhD; RobMcConnell, MD; Junhan Cho, PhD; Jessica L. Braymiller, PhD; Evan A. Krueger, PhD, MPH, MSW; Adam M. Leventhal, PhD JAMA Network Open, 2020, 3, (10), :e2019181. doi : 10.1001/jamanetworkopen.2020.19181   Abstract IMPORTANCE : Little is known about cannabis vaping trajectories across adolescence and young adulthood or the co-occurrence with nicotine vaping. OBJECTIVE : To evaluate nicotine vaping and cannabis vaping trajectories from late adolescence to young adulthood (18 years of age) and the extent of polysubstance vaping. DESIGN, SETTING, AND PARTICIPANTS : In this prospective cohort study, 5 surveys [...]

Lire la suite

Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler, 2020

Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington Jeremy Mennis, Gerald J. Stahler Drug and Alcohol Dependence, 2020, 210, 107960 Doi : 10.1016/j.drugalcdep.2020.107960   A B S T R A C T Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008–2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12–17 were used to model state treatment [...]

Lire la suite

Frequent Cannabis Use in Depression Tripled Over Past Decade, Batya Swift Yasgur, 2020

Frequent Cannabis Use in Depression Tripled Over Past Decade Batya Swift Yasgur, MA, LSW Medscape, August 19, 2020 Not only are individuals with depression at significantly higher risk for cannabis use compared with those without depression, this trend has increased dramatically over the last decade, new research shows. Investigators analyzed data from more than 16,000 US adults between the ages of 20 and 59 years and found that those with depression had almost twice the odds of any past-month cannabis use compared with those without depression. Odds rose from 1.5 in the 2005-2006 period to 2.3 in the 2015-2016 period. Moreover, the odds ratio (OR) [...]

Lire la suite

The association between cannabis use and mood disorders : A longitudinal study, Daniel Feingold et al., 2015

The association between cannabis use and mood disorders : A longitudinal study Daniel Feingold, Mark Weiser, Jürgen Rehme, Shaul Lev-Ran Journal of Affective Disorders, 2015, 172, 211–218. doi : 10.1016/j.jad.2014.10.006   a b s t r a c t Background : The association between cannabis use and mood disorders is well documented, yet evidence regarding causality is conflicting. This study explored the association between cannabis use, major depressive disorder (MDD) and bipolar disorder (BPD) in a 3-year prospective study. Methods : Data was drawn from waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). MDD and BPD were controlled at baseline [...]

Lire la suite

Cannabis Misconceptions Still Common Among MS Clinicians, Nancy Melville, Medscape.com, 2020

Cannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1   Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]

Lire la suite

Impact of COVID-19 on drug services and help-seeking in Europe, EMCDDA trendspotter briefing, May 2020

Impact of COVID-19 on drug services and help-seeking in Europe EMCDDA trendspotter briefing May 2020   The situation regarding public health responses to the COVID-19 pandemic is rapidly evolving. Up-to-date information can be found in the guidelines prepared by national public health sources and the regular updates from the European Centre for Disease Prevention and Control and the World Health Organization. The EMCDDA has created a COVID-19 resource hub for people who use drugs and drug service providers. Summary Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate [...]

Lire la suite